Boehringer Ingelheim: Parkinson Disease trials

The registry lists 42 Parkinson Disease studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 22 have results posted.

Phase 2 3Phase 3 11Phase 4 7No phase 22(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-DopaCompletedNCT03521635Phase 4Results posted
• Safety and Efficacy of Long-term Daily Use of Mirapex®-LA Tablets in Patients With Parkinson's DiseaseCompletedNCT01525641Results posted
• a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease PatientsCompletedNCT01361009Results posted
• Pramipexole Extended Release Versus Pramipexole Immediate Release for 18 Weeks in Chinese Parkinson's Disease (PD) PatientsCompletedNCT01191944Phase 3Results posted
• Kinetic Tremor in Parkinsons Disease: Its Course Under Pramipexole (Mirapexin®) Treatment and Impact on Quality of LifeCompletedNCT01100073Results posted
• Influence of Pramipexole Extended Release on Medication Adherence in Parkinson´s DiseaseCompletedNCT01097421Results posted
• Assessment of the Safety and Efficacy of Pramipexole Extended Release in Patients With Parkinson's Disease in Routine Clinical PracticeCompletedNCT01061567Results posted
• First Presentation of Parkinson Disease Patients to NeurologistCompletedNCT00802178Results posted
• Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole TreatmentCompletedNCT00651183Results posted
• Special Survey on Parkinson's Disease Patients Treated Long-term Use of PramipexoleCompletedNCT00615914Results posted
• Survey on PD Patients With Depressive SymptomsCompletedNCT00614575Results posted
• Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-DopaCompletedNCT00613301Results posted
• Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).CompletedNCT00601523Phase 3Results posted
• Long-term Safety Study of Open-label Pramipexole ER in Patients With Advanced PDCompletedNCT00577460Phase 3Results posted
• A 12-week Study of Pramipexole Extended Release (ER) in Patients With Parkinson's Disease (PD), Followed by a 52-week Long-term Treatment PeriodCompletedNCT00560508Phase 2/3Results posted
• Overnight Switch Trial From Pramipexole IR to Pramipexole ER in Patients With Early Parkinson DiseaseCompletedNCT00558025Phase 3Results posted
• Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD PatientsCompletedNCT00479401Phase 3Results posted
• Pivotal Study in Advanced Parkinsons Disease PatientsCompletedNCT00466167Phase 3Results posted
• A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) PatientsCompletedNCT00402233Phase 4Results posted
• Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)CompletedNCT00321854Phase 4Results posted
• Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive SymptomsCompletedNCT00297778Phase 4Results posted
• Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) PatientsCompletedNCT00144300Phase 4Results posted
• Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's DiseaseCompletedNCT02248220
• Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's DiseaseCompletedNCT02248207
• Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02248181
• Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02248168
• Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With PramipexoleCompletedNCT02236728
• Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's DiseaseCompletedNCT02233023Phase 4
• Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's DiseaseCompletedNCT02231905Phase 4
• The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02231294
• Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's DiseaseCompletedNCT02231255
• Pramipexole in Untreated and Levodopa-treated Parkinson's Disease PatientsCompletedNCT02177357Phase 3
• Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's DiseaseCompletedNCT02172573Phase 3
• Non-interventional Observational Study on WHO-5 Questionnaire Application in Parkinson's DiseaseCompletedNCT00752388
• Impulse Control Disorders in Parkinson's Patients Treated With Pramipexole and Other Agents (DOMINION Study)CompletedNCT00617019
• Special Survey on PD Patients With Renal DysfunctionCompletedNCT00613756
• Non-interventional Observational Study With Pramipexole: Impact on Non-motor Symptoms in Parkinson's DiseaseCompletedNCT00539214
• Profile of Depressive Symptoms in Parkinsons DiseaseCompletedNCT00349310
• Long-term Administration Study of SND 919 Tablets in Parkinson's DiseaseCompletedNCT00274131Phase 3
• Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's DiseaseCompletedNCT00240409Phase 3
• A Randomized, Double-blind, Placebo-controlled, Five Parallel Groups Efficacy and Safety Study of NS 2330 (Tesofensine) (0.125 mg, 0.25 mg, 0.5 mg and 1.0 mg) Administered Orally Once Daily Over 14 Weeks in Levodopa Treated Parkinson Patients With Motor FluctuationsCompletedNCT00148512Phase 2
• A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)CompletedNCT00148486Phase 2